Sibel Health today announced FDA 510(k) clearance of ANNE® Maternal, the world’s first fully wireless, comprehensive maternal-fetal monitoring platform.
PITTSBURGH, April 8, 2026 /PRNewswire/ — “Our intention is to create a more accurate and exact wearable device to determine the onset of the female ovulation cycle and consequently when a female human or animal is most likely to become pregnant after insemination,” stated one of the two inventors, from Gainesville, Virginia, “hence the invention of the Ovulonics device. Our design would provide an easy, convenient and accurate detection time for human or animal
Sabrina Martucci Johnson wants everyone to invest in her women’s health biotech Daré Bioscience. That means you, dear reader.
MILFORD, Mass., April 8, 2026 /PRNewswire/ — Waters Corporation (NYSE: WAT) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant milestone in expanding access to cervical cancer screening, and removing barriers that currently prevent many individuals from receiving routine screening.
Biomedical researchers have designed an injectable microgel to help reduce bleeding in infants who require surgical care. In an animal model, the engineered microgel reduced bleeding by at least 50%. The paper, “Hemostatic B-Knob Triggered MicroGels (BK-TriGs) to Address Bleeding in Neonates,” is published in the journal Science Advances.
Ovarian cancer remains the deadliest gynecologic cancer, largely because it is rarely found early. Symptoms are often vague, and existing screening approaches—such as blood tests and transvaginal ultrasound—can miss the disease at stages when treatment is most effective. In recent years, research has reshaped understanding of how many aggressive ovarian cancers begin, pointing not to the ovary itself, but to the fallopian tubes. That shift has created a need for tools that can safely examine these narrow structures for early changes linked to cancer.
Garmin users can now integrate with the temperature-powered Natural Cycles app, which turns Garmin skin temperature data into fertility insights for women’s health
Butterfly’s GA tool within its point-of-care ultrasound (POCUS) system is intended for rollout in regions with socioeconomic barriers to obstetric imaging services.
Researchers from the Technion—Israel Institute of Technology, together with collaborators from leading medical centers in the United States and Europe, have developed an artificial intelligence (AI) model that predicts both the risk of breast cancer recurrence and the likelihood that a patient will benefit from chemotherapy.
Scientists at the University of Utah (the U) have developed a new “lab-on-a-chip” device that uses artificial intelligence to rapidly predict cancer cell sensitivity to targeted therapies for children with T-cell acute lymphoblastic leukemia (T-ALL), an aggressive and difficult-to-treat cancer.